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Hendra virus (HeV) is an emerging paramyxovirus first isolated from cases of severe respiratory disease that fatally
affected both horses and humans. Understanding the mechanisms of host cell infection and cross-species transmission is
an important step in addressing the risk posed by such emerging pathogens. We have initiated studies to characterize the
biological properties of the HeV envelope glycoproteins. Recombinant vaccinia viruses encoding the HeV F and G open
reading frames were generated and glycoprotein expression was verified by metabolic labeling and detection using specific
antisera. Glycoprotein function and cellular tropism were examined with a quantitative assay for HeV-mediated membrane
fusion. Fusion specificity was verified through specific inhibition by anti-HeV antiserum and a peptide corresponding to one
of the a-helical heptad repeats of F. HeV requires both F and G to mediate fusion. Permissive target cells have been identified,
including cell lines derived from cat, bat, horse, human, monkey, mouse, and rabbit. Fusion negative cell types have also been
identified. Protease treatments of the target cells abolished fusion activity, suggesting that the virus is employing a
cell-surface protein as its receptor.
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Fusion of the membrane of enveloped viruses with the
plasma membrane of a receptive host cell is a prereq-
uisite for viral entry and infection and an essential step in
the life cycle of all enveloped viruses. The paramyxovi-
ruses are negative-stranded RNA-containing enveloped
viruses encompassing a variety of important human and
animal pathogens including measles virus (MeV), canine
distemper virus (CDV), human parainfluenza viruses
(hPIV) 1–4, respiratory syncytial virus (RSV), and simian
virus 5 (SV5) (reviewed in Lamb and Kolakofsky (2001)).
These viruses contain two principal membrane-an-
chored glycoproteins that appear as spikes projecting
from the envelope membrane of the viral particle when
imaged in the electron microscope. One glycoprotein is
associated with virion attachment to the host cell and,
depending on the particular paramyxovirus, has been
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121designated as the hemagglutinin–neuraminidase pro-
tein, the hemagglutinin protein (H), or the G protein,
which has neither hemagglutinating nor neuraminidase
activities. The second glycoprotein is the fusion protein
(F), which facilitates the membrane fusion event between
the virion and the host cell during virus infection (re-
viewed in Baker et al. (1999); Lamb (1993)). Following
virus attachment to a permissive host cell, fusion at
neutral pH between the virion and the plasma mem-
branes ensues, resulting in delivery of the nucleocapsid
into the cytoplasm (reviewed in Lamb and Kolakofsky
(2001)). In a related process, cells expressing these viral
glycoproteins at their surfaces can fuse with receptor-
bearing cells, resulting in the formation of multinucleated
giant cells (syncytia). The paramyxovirus F glycoprotein
shares several features with other viral membrane fusion
proteins, including the envelope glycoprotein of retrovi-
ruses like gp120/gp41 of HIV-1 and hemagglutinin of
influenza virus (reviewed in Hernandez et al. (1996)). The
biologically active F protein consists of two disulfide-
linked subunits, F1 and F2, that are generated by the
proteolytic cleavage of a precursor polypeptide known
as F0 (Klenk and Garten, 1994; Scheid and Choppin,
974). All paramyxoviruses studied to date, with the ex-
eption of SV5, require both the attachment and F glyco-
roteins for membrane fusion (Paterson et al., 1997). A
recise understanding of how the attachment and fusion
lycoproteins of the paramyxoviruses function in concert
n mediating this membrane fusion process has yet to be
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122 BOSSART ET AL.elucidated. Although evidence of physical interactions
has only been rarely detected, it is hypothesized that the
binding protein must somehow signal and induce a con-
formational change in F leading to virion/host cell mem-
brane fusion (Lamb, 1993).
In 1994, a new paramyxovirus, now called Hendra
virus (HeV) and recognized to be a member of the sub-
family Paramyxovirinae, was isolated from fatal cases of
espiratory disease in horses and humans and was
hown to be distantly related to MeV and other members
f the Morbillivirus genus (Murray et al., 1995). The out-
break occurred in the Brisbane suburb of Hendra and
resulted in the death of 13 horses and their trainer and
the nonfatal infection of a stablehand and a further 7
horses. At approximately the same time, in an unrelated
incident ;100 km north of Hendra, a 35-year-old man
experienced a brief aseptic meningitic illness after car-
ing for and assisting at the necropsies of two horses
subsequently shown to have died as a result of HeV
infection, and 13 months later the man suffered severe
encephalitis characterized by uncontrolled focal and
generalized epileptic activity (O’Sullivan et al., 1997). Sub-
sequent to these events, an outbreak of severe enceph-
alitis in people with close contact exposure to pigs in
Malaysia and Singapore occurred in 1998 (Centers for
Disease Control and Prevention, 1999). In all, more than
265 cases of encephalitis, including 105 deaths, had
been reported in Malaysia, and 11 cases, with one death,
were reported in Singapore. This may represent a near
40% fatality rate upon infection, because the incidence of
subclinical human infections during these episodes has
not been well defined. Follow-up studies indicated that
this virus was most closely related to HeV and was
named Nipah virus (NiV) after the small town in Malaysia
from which the first isolate was obtained from a fatal
human case (Chua et al., 1999, 2000; Goh et al., 2000;
Lee et al., 1999; Lim et al., 2000). HeV and NiV are now
two representatives of a new genus within the Paramyxo-
virinae subfamily called Henipavirus (Wang et al., 2001;
Wang and Eaton, in press).
Both HeV and NiV are unusual among the paramyxo-
viruses in their ability to infect and cause potentially fatal
disease in a number of host species, including humans,
and in that they have an exceptionally large genome.
Understanding the mechanisms of how viruses like
these emerge, mediate host cell infection, or undergo
cross-species transmission is an important step toward
determining how to address such emerging infectious
disease threats. Our approaches to examine HeV have
begun with the characterization of the virus’ envelope
glycoproteins, which facilitate the attachment and fusion
events during infection. HeV possesses a F glycoprotein
that likely mediates membrane fusion, and the attach-
ment glycoprotein has been designated G. Here we
report the development of a recombinant system to study
HeV using recombinant vaccinia viruses encoding the F
fand G open reading frames (ORFs). HeV F and G expres-
sion was verified by metabolic labeling and detection
using specific antisera. The cellular tropism of HeV was
examined using a quantitative assay for HeV-mediated
fusion. Fusion specificity was also verified through spe-
cific inhibition with a peptide corresponding to one of the
a-helical heptad repeats of F and rabbit anti-HeV serum,
which could specifically inhibit the fusion assay. HeV
requires both F and G to mediate fusion. Permissive
target cells have been identified, including those derived
from cat, bat, horse, human, simian, mouse, and rabbit.
Putative receptor negative cell types have also been
identified, and protease treatments of target cells abol-
ished fusion activity, suggesting that the virus is employ-
ing a cell-surface protein as its receptor.
RESULTS
Expression of Hendra virus F and G glycoproteins
HeV is classified as a zoonotic, biosafety level 4
(BSL-4) agent and thus its manipulation under laboratory
conditions is highly restricted. To readily examine the
biochemical and functional properties of the virus’ enve-
lope glycoproteins, the viral proteins responsible for host
cell attachment and virion entry, we employed the vac-
cinia virus-based recombinant expression system
(Broder and Earl, 1999; Carroll and Moss, 1997). For the
production of recombinant-expressed HeV envelope gly-
coproteins, the HeV F and G ORFs (Gould, 1996; Wang et
al., 2000; Yu et al., 1998) were subcloned into the vaccinia
virus promoter driven expression vector pMC02 (Carroll
and Moss, 1995) and recombinant viruses were prepared
using standard techniques as detailed under Materials
and Methods. In order to develop reagents to biochem-
ically detect the HeV envelope glycoproteins, anti-F and
anti-G peptide-specific rabbit antisera were prepared
(see Materials and Methods). These antisera were ti-
tered using a peptide-specific ELISA and specificity was
further cross-analyzed by competition ELISA. The HeV
envelope glycoproteins F and G were produced in cell
culture either by transient transfection with the appropri-
ate plasmid construct or by infection with recombinant
vaccinia virus. Shown in Fig. 1A is recombinant vaccinia
virus-expressed HeV F immunoprecipitated with peptide-
specific (anti-F2 or anti-G) and virus-specific antisera.
The vaccinia-expressed HeV F appeared predominantly
as the uncleaved precursor protein, F0, and as the pro-
essed F1 subunit. The F2 subunit (;19 kDa) was not
eadily detected under these conditions, likely due to a
ombination of the amount and specific activity of the
etabolically labeled polypeptide. This profile of the HeV
was quite similar to that of several other paramyxovirus
glycoproteins (Bagai and Lamb, 1995; Nussbaum et al.,
995; Yao et al., 1997), with apparent molecular masses
or F0 of ;61 kDa and F1 ;49 kDa, and identical to the F
polypeptides derived from purified HeV particles (Michal-
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123HENDRA VIRUS ENVELOPE GLYCOPROTEINSski et al., 2000; Murray et al., 1998; Wang, 1998). Shown
in Fig. 1B is metabolically labeled recombinant vaccinia
virus-expressed HeV G immunoprecipitated with rabbit
anti-peptide and anti-HeV antisera. The vaccinia-ex-
pressed HeV G possessed an apparent molecular mass
of ;75 kDa, also quite similar to HeV G derived from
purified HeV virions (Murray et al., 1998; Wang et al.,
1998), as well as to the H proteins from MeV and CDV
(Nussbaum et al., 1995). The profiles of the vaccinia-
xpressed F and G glycoproteins observed using rabbit
nti-HeV antiserum were identical to those obtained with
he peptide-specific antisera; compare lanes 2 and 4 in
ach panel of Fig. 1.
yncytia formation mediated by HeV envelope
lycoproteins
To evaluate whether the F and G ORFs encoded func-
ional HeV envelope glycoproteins, it was necessary to
emonstrate their ability to mediate membrane fusion. In
nitial experiments, the plasmids containing either HeV F
r G were transfected alone or in combination into sev-
ral cell lines that included murine 3T3, human 293T,
imian BSC-1, human TK2, and human HeLa cells. When
the HeV F or HeV G constructs or the plasmid vector
FIG. 1. Expression of recombinant HeV F and G glycoproteins. The F
and G glycoprotein ORFs were subcloned into vaccinia virus promoter-
driven expression vector pMC02 (Carroll and Moss, 1995). HeLa cells
were infected with HeV F or G encoding recombinant vaccinia viruses
and incubated for 16 h at 37°C. Beginning at 6 h postinfection, the cells
were labeled overnight with [35S]methionine/cysteine. Lysates were
prepared in buffer containing Triton X-100 and clarified by centrifuga-
tion. Immunoprecipitation was performed with rabbit polyclonal anti-
serum against synthetic F2- or G-specific peptides or rabbit anti-HeV
ntiserum (see Materials and Methods), followed by Protein G–Sepha-
ose. The radiolabeled proteins were resolved by 10% SDS–PAGE
nder reducing conditions and detected by fluorography. (A) HeV F
mmunoprecipitated lysates; lanes 1 and 2 with rabbit anti-HeV anti-
erum, lanes 3 and 4 with rabbit anti-F2 peptide antiserum. (B) HeV G
mmunoprecipitated lysates; lanes 1 and 2 with rabbit anti-HeV anti-
erum, lanes 3 and 4 with rabbit anti-G peptide antiserum. Lanes 1 and
of each panel are precipitates prepared from lysates of cells infected
ith a control vaccinia virus.control was transfected into cells individually, no syncy-
tia formation was evident in any of several cell lines
a
2examined (not shown). However, when the HeV F and G
plasmid constructs were cotransfected, syncytia forma-
tion was evident in all cell lines tested with the exception
of HeLa (not shown), with some variation noted in the
average size of individual syncytia among the different
cell types over the same incubation period. Since HeLa
cells were unable to support syncytia formation the pre-
sumption was that these cells lack a functional HeV
receptor and would not serve as permissive target cells
for HeV-mediated fusion, thus they were chosen as the
HeV F- and G-expressing effector cell populations for
subsequent membrane fusion experiments. In so doing,
HeV glycoprotein-expressing HeLa effector cells would
not undergo spontaneous membrane fusion and would
also likely prevent possible intracellular receptor/enve-
lope glycoprotein complex formation, which might inter-
fere in quantitative membrane fusion assessments.
Shown in Fig. 2 are the results observed with recombi-
nant vaccinia virus-expressed HeV glycoproteins in
HeLa effector cell populations mixed with murine 3T3
cell targets as a representative example, where syncytia
are evident only when F and G are coexpressed (Fig. 2D).
Like most other paramyxoviruses that have been exam-
ined, HeV-mediated fusion and syncytia formation re-
quired the expression of both the F and G glycoproteins
to mediate syncytia formation. These data demonstrate
that the cloned ORFs for the predicted HeV F and G
genes do encode functional glycoproteins.
Quantitation of HeV-mediated fusion
Although syncytia formation was evident, visual obser-
vation is only semiquantitative and possesses low sen-
sitivity for measuring viral glycoprotein-mediated mem-
brane fusion. Previously, we developed a functional re-
porter-gene system for the examination of the membrane
fusogenic properties of the envelope glycoprotein of
HIV-1 (Broder and Berger, 1995; Broder et al., 1994; Nuss-
baum et al., 1994). This system is based on gene expres-
sion using the recombinant vaccinia virus system
(Berger et al., 1995), where in addition to the viral enve-
lope glycoproteins and viral receptors being expressed
on effector and target cell populations, respectively, one
cell population also expresses bacteriophage T7 RNA
polymerase and the other a T7 promoter-driven Esche-
richia coli LacZ cassette (see Materials and Methods).
Thus, cell–cell fusion results in the specific production of
b-galactosidase (b-Gal), which can be quantified. This
ssay has proven especially useful in the study of enve-
ope glycoproteins derived from viruses that employ a
H-independent mechanism of membrane fusion for
irion entry (Alkhatib et al., 1996b; Bagai and Lamb, 1995;
roder and Berger, 1995; Chung et al., 1999; Feng et al.,
996; Krueger et al., 2001; Nussbaum et al., 1995; Pastey
nd Samal, 1997; Santoro et al., 1999; Takikawa et al.,
000). Using this assay, HeV glycoprotein-expressing
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124 BOSSART ET AL.HeLa effector cells were prepared and mixed with vari-
ous target cell populations. Typically, the target and ef-
fector cell populations are assessed in duplicate or trip-
licate in 96-well plate format and incubated for 2–4 h
following mixing. Cell lysates are prepared and pro-
cessed for b-Gal quantification. The results shown in Fig.
are the HeV-mediated fusions measured in the same
eries of cell lines that was examined in the syncytia
ormation assay. Some differences in fusion activity as
easured by the level of b-Gal activity were observed
between those cell lines that were syncytia positive, with
the mouse 3T3 target cells consistently yielding the high-
est levels. HeLa target cells were again negative for
HeV-mediated fusion, thus corroborating the syncytia
assay results, and since this cell-fusion reporter gene
assay is independent of syncytia formation, it appears
FIG. 2. Syncytia formation mediated by Hendra virus glycoprotein-
xpressing cells. HeLa cells were infected with vaccinia virus recom-
inants encoding HeV F (B), HeV G (C), both F and G glycoproteins (D),
r a control vaccinia virus (A), along with a vaccinia virus recombinant
ncoding T7 RNA polymerase. Partner 3T3 cells were infected with the
. coli LacZ-encoding reporter vaccinia virus vCB21R. The HeV glyco-
rotein-expressing cells (1 3 105) were mixed with the 3T3 partner cells
1 3 105) in duplicate wells of a 96-well plate and incubated at 37°C.
fter 3 h the cells were fixed and stained with crystal violet and
hotographs were taken at 4003 magnification.that HeLa cells are indeed fusion nonpermissive. It is
also evident from this experiment that efficient HeV-
a
Gmediated membrane fusion requires the presence of
both the F and the G glycoproteins.
Specificity of HeV-mediated fusion activity
To further assess the specificity and utility of the HeV-
mediated fusion system we sought ways to specifically
inhibit the cell-fusion process. There have been consid-
erable advances in the understanding of the structural
features and development of mechanistic models of how
several viral envelope glycoproteins function in driving
the membrane fusion reaction (reviewed in Chan and
Kim (1998); Skehel and Wiley (1998); Weissenhorn et al.
(1999)). One important feature of many of these fusion
glycoproteins is the presence of two a-helical domains,
referred to as heptad repeats, that are involved in the
formation of a trimer-of-hairpins structure (Hughson,
1997; Singh et al., 1999). These domains are also referred
o as the amino (N)-terminal and the carboxyl (C)-termi-
al heptad repeats, and peptides corresponding to either
f these domains can inhibit the activity of the viral fusion
lycoprotein when present during the fusion process.
ere we noted two putative a-helical domains in the HeV
F glycoprotein analogous to the heptad repeats present
in SV5 F. One HeV F heptad domain is proximal to the
fusion peptide of F1 (N-terminal heptad repeat), and the
other is very close to the predicted transmembrane do-
main of F1 (C-terminal heptad repeat) (Fig. 4A). Helical
heel analysis revealed a high degree of sequence
omology with the important functional residues of the
V5 heptad repeats (Fig. 4C) (Joshi et al., 1998). To
etermine whether these structures play a similar impor-
ant role in HeV fusion, a 42-amino-acid peptide (FC1)
erived from the C-terminal heptad repeat (Fig. 4B) was
ynthesized and tested for its ability to interfere with
eV-mediated fusion. An available nonspecific 44-ami-
o-acid peptide derived from the cytoplasmic tail of the
nterleukin-2 (IL-2) receptor gamma chain was used as
n irrelevant peptide control. Shown in Fig. 5 are the
esults of HeV-mediated fusion obtained in the presence
f a series of FC1 peptide, or irrelevant control peptide,
oncentrations. The FC1 peptide could potently inhibit
usion in a dose-dependent manner and was completely
nhibitory in the nanomolar range, with an IC50 of 4.4 nM.
hese data strongly suggest that the HeV fusion mech-
nism is likely highly analogous to other viral fusion
ystems where a trimer of hairpins has been hypothe-
ized to form. The specific inhibition of the HeV-mediated
usion assay by a synthetic peptide that targets the F
lycoprotein further demonstrates the specificity of this
eV-mediated cell fusion assay.
To explore the utility of the HeV fusion assay, we
ested the ability of HeV-specific antiserum to inhibit
usion. Rabbit anti-HeV antiserum was serially diluted
nd added to HeLa effector cells expressing HeV F and
glycoproteins. Target cells were immediately added
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125HENDRA VIRUS ENVELOPE GLYCOPROTEINSand mixed, and fusion was allowed to proceed for 3 h
(see Materials and Methods). Shown in Fig. 6 are the
HeV fusion results obtained in the presence of HeV-
specific rabbit antiserum in comparison to normal rabbit
serum. There was little nonspecific inhibitory activity
exhibited by the normal rabbit sera and was maximally
;15%, at the highest sera concentrations (data not
shown), whereas inhibition by the HeV-specific anti-
serum could block the fusion assay by .90% at a 1:50
dilution and there was approximately 50% inhibition at a
1:200 dilution. These results were quite significant in
light of the high levels of expressed HeV F and G enve-
lope glycoproteins on the surfaces of the HeLa effector
cells, and the potency of inhibition observed here may be
related to the requirement of two envelope glycoproteins
in the HeV fusion process and the polyclonal nature and
characteristics of the antibodies present. Indeed, the
peptide-specific anti-F2 and anti-G rabbit sera developed
ere had no inhibitory effect when examined (not
hown), which is perhaps not unexpected since it is
ighly likely that peptide-specific antisera would contain
o conformation-dependent antibody reactivities and be
eactive to only a limited subset of epitopes, unlike se-
um derived from whole HeV-immunized rabbits.
rotease treatment of target cells destroys HeV-
ediated fusion activity
FIG. 3. Quantitation of HeV-mediated cell fusion. HeLa cells were
glycoproteins, or none, along with a vaccinia recombinant encoding T7
with the E. coli LacZ-encoding reporter vaccinia virus vCB21R. The HeV
(1 3 105) in duplicate wells of a 96-well plate. After 3 h at 37°C, Nonide
b-Gal activity in target cell populations alone is indicated. The b-Gal act
olymerase-encoding vaccinia virus and no vaccinia recombinants enThe utility of the HeV-mediated fusion assay com-
ined with the observation that cell lines derived fromhe same species may be either permissive or resis-
ant to fusion prompted an examination of the nature of
he unknown HeV receptor, and permissive target and
ffector cells were subjected to various pretreatments
rior to their use in the cell fusion assay. HeV contains
either hemagglutinating nor neuraminidase activity
Murray et al., 1995), suggesting that the cellular re-
eptor may not be sialic acid (Yu et al., 1998). We
treated effector cells with excess sialic acid over a
range of concentrations and in no case was any in-
hibitory effect observed on HeV-mediated fusion (data
not shown). We have also shown that neuraminidase
treatment of Vero cells does not inhibit HeV infection
but can abrogate their susceptibility to newcastle disease
virus (NDV) and influenza virus A, two viruses that employ
sialic acid as receptors (B. T. Eaton, unpublished results).
Together, these data are in agreement with the notion that
the HeV G protein is not employing sialic acid moieties as
receptors. However, protease treatment of target cells with
increasing doses of either proteinase K or trypsin resulted
in significant decreases in subsequent HeV-mediated fu-
sion in a dose-dependent manner (Fig. 7). The absolute
values of b-Gal reporter activity are different between the
two conditions because these are independent experi-
ments. Together, these results support the hypothesis
that HeV, like one of its most closely related family
with vaccinia recombinants encoding HeV F, HeV G, both F and G
lymerase (effector cells). Each designated target cell type was infected
rotein-expressing cells (1 3 105) were mixed with each target cell type
as added and b-Gal activity was quantitated. The level of background
m target cells mixed with HeLa partner cells infected with only T7 RNA
HeV glycoproteins is indicated as “none.”infected
RNA po
glycop
t-P40 w
ivity fromembers, MeV, is employing a surface-expressed pro-
tein as a functional receptor for attachment and fusion.
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126 BOSSART ET AL.Species tropism of HeV-mediated cell fusion
Unlike other paramyxoviruses, HeV has been clearly
implicated in cross-species infections, including human,
that can result in significant morbidity and mortality. Us-
ing the HeV-mediated cell fusion system developed here,
we examined the target cell species tropism of HeV
using a battery of available cell lines and primary cul-
tures. Shown in Fig. 8, are the cell fusion results obtained
with a series of alternate animal species cell lines. Tar-
get cells derived from an insectivorous bat, cells from
horse (the first animal to contract HeV disease), and
human TK2 cells were all capable of permissive fusion
with cells expressing the HeV F and G glycoproteins. Cat
embryo cells were also permissive targets for HeV-me-
diated fusion, and cats have been shown to be highly
FIG. 4. Location of HeV F glycoprotein heptad repeats. (A) Diagram of
B) Amino acid sequence of the C-terminal heptad repeat of HeV F; bold
hat are capable of forming a leucine zipper. (C) Helical wheel represe
he helical wheel indicate important residue locations on the helix stru
t al., 1998). Point a of one N-terminal heptad is thought to interact wi
of the N-terminal heptad is thought to interact with point a of the C-ter
oint d of the C-terminal heptad in an antiparallel orientation. In all, i
eptad repeats of three SV5 F proteins mediate the necessary prote
nlarged underlined amino acids represent HeV F residues that are ide
ut not underlined amino acids are hydrophobic conservative substitususceptible to HeV infection, manifesting pathology very
similar to that observed in naturally and experimentallyinfected horses (Hooper et al., 2001). These results illus-
trate that the cell fusion tropism demonstrated by our
functional recombinant assay parallels natural and ex-
perimental HeV infections. Other cells that were negative
for fusion were pig kidney and duck embryo cell lines, as
well as primary chick embryo fibroblasts. Although rab-
bits, monkeys, and mice have not been shown to be
infected by HeV in nature, it is of interest that these cells
also express the HeV receptor. The susceptibility of rab-
bits to HeV infection remains to be verified. In all cases,
both HeV F and G together were required to mediate
efficient fusion with all permissive target cell populations
(Fig. 8). Finally, because both permissive and nonpermis-
sive human target cell lines have been identified, we
chose to examine primary blood cell populations of hu-
V F glycoprotein depicting important structural and functional elements.
d enlarged amino acids represent the important hydrophobic residues
of the N- and C-terminal heptad repeats of HeV F. Boldface points on
f the F protein of SV5 that mediate protein–protein interactions (Joshi
t d of another SV5 F N-terminal heptad in a parallel orientation. Point
eptad, and point g of the N-terminal heptad is believed to interact with
othesized that three N-terminal heptad repeats and three C-terminal
tein interactions that stabilize the fusogenic SV5 F trimer formation.
those found in the N- and C-terminal heptad repeats of SV5; enlarged
HeV F as compared to SV5 F.the He
face an
ntation
cture o
th poin
minal h
t is hyp
in–proman peripheral blood lymphocytes (PBL) and macro-
phages. Both stimulated and unstimulated PBL and mac-
v
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127HENDRA VIRUS ENVELOPE GLYCOPROTEINSrophages were examined and compared to HeLa target
cells; however, in no case was significant fusion ob-
served (Fig. 9). It should be noted that the level of signal
FIG. 5. Specificity of HeV-mediated fusion. HeLa cells were infected
with a vaccinia recombinant encoding T7 RNA polymerase (effector ce
accinia virus vCB21R (target cells). Peptides were diluted and added t
were then added (1 3 105). Each peptide concentration was performed
nd b-Gal activity was quantitated.
FIG. 6. HeV fusion and blocking by specific rabbit antiserum. HeLa a
were diluted and added to the HeV glycoprotein-expressing cells (1 3 105) in
Each serum dilution was performed in duplicate wells. After 3 h at 37°C, Noobserved is extremely low and that the signal observed
with HeLa cell targets is less than twice the vector
control and not considered significant. The hypothesis
accinia recombinants encoding the HeV F and G glycoproteins along
man TK2 cells were infected with the E. coli LacZ-encoding reporter
eV glycoprotein-expressing cells (1 3 105) in a 96-well plate; TK2 cells
icate in 96-well plate format. After 3 h at 37°C, Nonidet-P40 was added
cells were prepared as described in the legend to Fig. 5. Rabbit serawith v
lls). Hu
o the Hnd TK296-well plate format and TK2 target cells were then added (1 3 105).
nidet-P40 was added and b-Gal activity was quantitated.
lm 0 was
128 BOSSART ET AL.that HeV utilizes a cellular protein receptor in the pro-
cess leading to fusion and syncytium formation as well
as the fact that HeLa cells lack this receptor or at least
a functional receptor, coupled with this highly sensitive
and specific HeV-mediated fusion system, provides an
avenue for receptor identification.
FIG. 7. Protease treatment of target cells destroys HeV-mediated fus
egend to Fig. 5. TK2 target cells were treated with different concentrati
with 10 ml of EMEM-10, washed once, and recounted. HeV glycoprotein
ixed in 96-well plate format in duplicate. After 3 h at 37°C, Nonidet-P4
derived from independent experiments.
FIG. 8. Species tropism of HeV-mediated cell fusion. HeLa effector ce
cell type was infected with the E. coli LacZ-encoding reporter vaccinia virus vC
described in the legend to Fig. 5.DISCUSSION
The results presented here have laid the groundwork
for studying the fusion and attachment membrane glyco-
proteins of the newly emerging Hendra virus. The ge-
netic and biological features of HeV as well as the
rmissiveness. HeLa and TK2 cells were prepared as described in the
ither trypsin or proteinase K for 2 min at room temperature, quenched
sing cells (1 3 105) and protease-treated TK2 cells (1 3 105) were then
added and b-Gal activity was quantitated. The data shown are results
prepared as described in the legend to Fig. 3. Each designated targetion pe
ons of e
-expreslls were
B21R. Cell populations were mixed and cell fusion was measured as
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129HENDRA VIRUS ENVELOPE GLYCOPROTEINSrelated NiV have placed them into a new genus, Heni-
avirus, in the Paramyxovirinae subfamily (Eaton, 2001;
ield et al., 2001; Hooper et al., 2001; Wang et al., 2001, in
press). Indeed, HeV and NiV are somewhat unique
among the paramyxoviruses in their ability to cause
severe and fatal disease in several animal species and
humans. Understanding the mechanisms of how viruses
like these can emerge, mediate host cell infection, and
perform cross species transmission is an important step
toward determining how to address new infectious dis-
ease threats such as these.
Here we report the development of a recombinant
expression system to examine the membrane glycopro-
teins of HeV and describe several features of their func-
tional activity. Similar results have been recently ob-
tained in our laboratory with the membrane glycopro-
teins of NiV (Bossart and Broder, unpublished results).
Radioimmunoprecipitation using anti-HeV peptide-spe-
cific sera and rabbit anti-HeV antiserum showed that
recombinant vaccinia virus-expressed HeV F and G gly-
coproteins were comparable to the cognate proteins in
purified virus (Murray et al., 1998). The molecular mass of
the F0 precursor was ;61 kDa and the processed F1
subunit ;49 kDa. The F2 subunit, ;19 kDa, was not
bserved biochemically using our available reagents.
he failure of F2 detection by either antiserum could be
ue to the paucity of F2 antibodies, but is more likely
related to assay sensitivity. Nevertheless, F2 is present
based on the functionality of HeV F glycoprotein in fusion
and the fact that the anti-peptide antiserum used is
specific for an F2 sequence. In addition, we have ob-
FIG. 9. Primary human cell tropism of HeV-mediated cell fusion. Hu
Stimulated PBL were prepared by culturing cells with 3 mg/ml phytoh
described in the legend to Fig. 3. Each designated target cell type was
populations were mixed and cell fusion was measured as described ierved a similar lack of F2 detection in radioimmunopre-
ipitation of functional MeV and CDV F glycoproteins
t
aNussbaum et al., 1995). The recombinant expressed G
lycoprotein was ;75 kDa. Both these glycoproteins
ave several predicted N-linked glycosylation sites
Michalski et al., 2000) and studies are under way to
xamine which sites are utilized and are important for
iological function. Based on the similarity in molecular
eights in comparison to other members of the
aramyxoviridae the F and G glycoproteins of HeV are
ndoubtedly N-glycosylated at one or more sites.
The functionality of the HeV F and G glycoproteins was
mmediately apparent through recombinant expression
nd the appearance of syncytia among cell populations
xpressing both HeV F and G glycoproteins. Indeed, the
eV glycoproteins were functionally expressed in pilot
xperiments prior to the availability of antiserum for bio-
hemical detection. By adapting our cell–cell fusion re-
orter-gene assay to the HeV-mediated fusion system
e were able to systematically examine, in a quantitative
anner, a battery of target cell populations representing
variety of cell types and animal species. In so doing,
nd more importantly for the development of strategies
o identify the receptor utilized by HeV, several cell lines
nd some primary cell types were found to be likely
eceptor-negative for HeV. Among these possible recep-
or-negative cell types were the human HeLa cell line
nd primary human PBL and macrophages. It was some-
hat surprising that pig cells were negative, in light of
he observation that pigs are a natural target of the
elated NiV in nature. The examination of additional pig
ell lines and or primary cells will be undertaken when
hey become available. In general, however, the detec-
BL and macrophage cultures were incubated overnight prior to use.
lutinin for 3 days prior to use. HeLa effector cells were prepared as
ed with the E. coli LacZ-encoding reporter vaccinia virus vCB21R. Cell
gend to Fig. 5.man P
emaggion of HeV-mediated fusion correlated well with those
nimal species known to be permissive for experimental
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130 BOSSART ET AL.HeV infection, such as horse, cat, and bat. Although we
examined an insectivorous bat cell line, the natural res-
ervoir of HeV appears to be a frugiverous bat. Recently it
was found that approximately 50% of Australian fruit bats,
commonly known as flying foxes, have antibodies to HeV,
and HeV-like viruses have been isolated from bat uterine
fluids; it appears that these animals are the natural host
for the virus (Field et al., 2001; Halpin et al., 1999, 2000;
Young et al., 1996). Finally, the generation of very high
titers of anti-HeV antibodies following administration of a
single dose of HeV to rabbits suggests that such animals
may be susceptible (Westbury et al., 1995) and the sus-
ceptibility of rabbit kidney cells to HeV-mediated fusion is
consistent with this suggestion. However, some caution
must be exercised in correlating in vivo susceptibility to
infection with the ability to form syncytia in an in vitro
system. For example, the capacity of mouse L2 cells to
form syncytia contrasts with the failure of HeV to infect
BALB/c mice by intranasal or parental routes (B. T. Eaton,
unpublished results).
Until recently, MeV, a morbillivirus and one of the
viruses most closely related to HeV and NiV, was the only
paramyxovirus shown to be capable of employing a cell-
surface protein as functional receptor. MeV vaccine
strains, in contrast to field isolates, can efficiently employ
CD46 as a functional receptor (Naniche et al., 1993) and
MeV H glycoprotein has been shown to specifically com-
plex with CD46 (Nussbaum et al., 1995). Further, MeV
field isolates as well as vaccine strains have recently
been shown to be capable of utilizing signaling lympho-
cyte activation molecule (SLAM; CD150) (Tatsuo et al.,
2000, 2001). SLAM is also capable of serving as a re-
ceptor for several other morbilliviruses (Tatsuo et al.,
2001). Here we assessed the nature of the unknown HeV
cellular receptor using the cell–cell fusion assay and
found that protease treatment of permissive target cells
inhibits HeV-mediated membrane fusion. Similar experi-
ments in the characterization of HIV-1 envelope-medi-
ated cell–cell fusion had also demonstrated this inhibi-
tion, where the CD4 receptor is readily removed from the
cell surface by trypsin (Broder et al., 1993). We hypothe-
size that since the HeV attachment glycoprotein has
neither hemagglutinin nor neuraminidase activities, that
protease treatment prevents fusion of an otherwise per-
missive target cell, and that certain cell lines from the
same species can be clearly positive or negative for
fusion, HeV is likely to utilize a surface-expressed protein
receptor for virus entry and infection. The cell–cell fusion
system described here is ideally suited to use in an
expression cloning strategy for identifying the HeV re-
ceptor as was successfully done to discover the first
HIV-1 coreceptor (Feng et al., 1996).
All viral membrane glycoproteins that are the media-
tors of membrane fusion, virion attachment, or both are
invariably oligomeric (Doms et al., 1993). Considerable
advances in the understanding of the structural featuresof these oligomeric viral envelope glycoproteins have
been attained in recent years and have centered on the
influenza virus and HIV systems. A notable structural
feature of many of these fusion glycoproteins is the
presence of two a-helical domains referred to as heptad
epeats (Chambers et al., 1990; de Groot et al., 1987) that
re important for both oligomerization and function of the
lycoprotein, where they are involved in the formation of
trimer-of-hairpins structure (Hughson, 1997; Singh et
l., 1999). Peptides corresponding to either of these do-
ains can potently inhibit the fusion process, first noted
ith sequences derived from the gp41 subunit of HIV-1
nvelope glycoprotein (Jiang et al., 1993; Wild et al.,
1994). Inhibition of the formation of the trimer-of-hairpins
structure inhibits the fusion process, and this mecha-
nism has been modeled and described by several
groups (Chan and Kim, 1998; Munoz-Barroso et al., 1998;
Rimsky et al., 1998; Root et al., 2001; Russell et al., 2001).
ndeed, the development and clinical application of fu-
ion inhibitors, as antiviral therapies for HIV-1, have been
direct result of this area of research.
Recently, an a-helical trimeric core complex was de-
fined in the F protein of SV5 and is also believed to be
either the fusion competent structure or the structure
formed after fusion has occurred, analogous to HIV-1
gp41 (Baker et al., 1999; Dutch et al., 1999; Lamb et al.,
1999). Similarly, the fusion protein core of RSV has also
been defined (Zhao et al., 2000). In addition, peptide
sequences from the N-terminal and/or C-terminal hep-
tads of the F glycoproteins of SV5, MeV, RSV, hPIV, NDV,
and Sendai virus have been shown to be potent inhibi-
tors of membrane fusion (Joshi et al., 1998; Lambert et al.,
1996; Rapaport et al., 1995; Wild and Buckland, 1997;
Young et al., 1997, 1999). Here we analyzed the heptad
repeats of HeV F using helical wheel diagrams and
identified the sequences that would be likely inhibitors of
HeV-mediated fusion. We then examined the specificity
of our recombinant HeV fusion system using a synthetic
42-amino-acid peptide (FC1) corresponding to the HeV F
C-terminal heptad. The FC1 peptide could completely
inhibit HeV-mediated fusion in the nanomolar range (IC50
of 4.4 nM). The FC1 peptide is currently being evaluated
as an inhibitor of live HeV infection under BSL-4 condi-
tions and may represent a therapeutic avenue for both
HeV and NiV infections. Indeed, the HeV F C-terminal
heptad peptide was also capable of inhibiting recombi-
nant NiV-mediated fusion at slightly lower efficiencies,
likely due to several mismatches in the heptad sequence
(Bossart and Broder, unpublished results).
HeV cell–cell fusion was also characterized using
HeV-specific rabbit antiserum, which could block the
cell–cell fusion assay with considerable efficiency. In
addition, NiV-specific rabbit sera could block HeV-medi-
ated fusion at lower levels of efficiency (not shown) and
this would be in agreement with the observed antigenic
cross-reactivity seen with HeV and NiV (Daniels et al.,
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131HENDRA VIRUS ENVELOPE GLYCOPROTEINS2001). Because this assay can be performed under BSL-2
conditions and is highly adaptable to high-throughput
screening, it may be a useful tool in the titering of
neutralizing antiserum outside BSL-4 containment. Ex-
periments are under way to make comparative assess-
ments of this cell–cell fusion assay with live HeV and NiV
neutralization assays.
In summary, we have established a recombinant sys-
tem to express and characterize the HeV F and G mem-
brane glycoproteins and study the HeV-mediated mem-
brane fusion process. We have shown that efficient
membrane fusion requires both the F and the G glycop-
roteins as is seen for almost all other paramyxoviruses.
In addition, fusion can be specifically inhibited with ei-
ther antiserum or targeted peptides, and to a significant
degree fusion parallels observed and experimental HeV
infection. We have also identified possible receptor-neg-
ative cell types. These preliminary studies have laid the
foundation for numerous approaches to develop new
reagents and to examine the many features of the fusion
and attachment glycoproteins of this interesting and
unique emerging paramyxovirus.
MATERIALS AND METHODS
Cell lines
The following cell lines were obtained from the Amer-
ican Type Culture Collection (ATCC): HeLa cells (ATCC
CCL 2); BSC-1 (ATCC CCL 26); CV-1 (ATCC CCL 70);
HuTK2143B (TK2) (ATCC CRL 8303); RK-13 (rabbit) (ATCC
CCL 37); Equus caballus (horse) (ATCC CCL-57); Sus
crofa (pig) (ATCC CL-101); Tadarida brasilliensis (bat)
ATCC CCL-88). Mouse L2 cells were provided by An-
hony Maurelli (Uniformed Services University, Bethesda,
D). Human PBL and macrophages were provided by
zanko Stantchev (Uniformed Services University, Be-
hesda, MD). Primary chick embryo fibroblasts (CEF)
ere provided by Norman Cooper (National Institutes of
ealth, Bethesda, MD). 293T, 3T3, cat embryo, and duck
mbryo cell lines were provided by Jay A. Levy (Univer-
ity of California, San Francisco, San Francisco, CA).
ulture conditions
HeLa, mouse L2, 3T3, 293T, and human macrophage
ell monolayers were maintained in Dulbecco’s modified
agle’s medium (Quality Biologicals, Gaithersburg, MD)
upplemented with 10% cosmic calf serum (CCS) (Hy-
lone, Logan, UT) and 2 mM L-glutamine (DMEM-10).
SC-1, CV-1, TK2, and CEF cell monolayers were main-
ained in Eagle’s minimal essential medium (EMEM)
Quality Biologicals) supplemented with 10% CCS and 2
M L-glutamine (EMEM-10). Duck embryo, cat embryo,
and human PBL were maintained in RPMI 1640 (Quality
Biologicals) supplemented with 10% CCS and 2 mM
L-glutamine (RPMI-10). Rabbit and horse cell monolayersere maintained in enriched EMEM (Quality Biologicals)
upplemented with 10% CCS, 1 mM sodium pyruvate,
nd 2 mM L-glutamine. Bat cell monolayers were main-
tained in enriched EMEM containing 0.85 g/L sodium
bicarbonate, 2 mM L-glutamine, and 10% CCS. Pig cell
monolayers were maintained in Medium 199 (Quality
Biologicals) containing 1.5 g/L sodium bicarbonate, 2
mM L-glutamine, and 3% CCS. All cell cultures were
aintained at 37°C in a humidified 5% CO2 atmosphere.
Plasmids and recombinant vaccinia viruses
For expression of recombinant HeV F and G glyco-
proteins, the F and G glycoprotein ORFs were sub-
cloned into the vaccinia virus promoter-driven expres-
sion vector pMC02 (Carroll and Moss, 1995). The HeV
F ORF was initially PCR amplified from plasmid
pCP514 (HeV F gene in pFastBac1) (Gould, 1996; Wang
et al., 2000) using primers 59-GTTTAAACGTCGACATG-
GCTACACAAGAGGTCAGG-39 (KB1) and 59-GTTTA-
AACGTCGACGATTGTAGTGTATTTTATGTT-39 (KB3). The
HeV G ORF was PCR amplified from plasmid pCP484
(HeV G gene in pFastBac1) (Wang et al., 2000; Yu et al.,
1998) using primers 59-GTTTAAACGTCGACCACCAT-
GATGGCTGATTCCAAATTGGTAAGC-39 (KB7) and
59-GTTTAAACGTCGACCAATCAACTCTCTGAACATTG-
GGCAGGTATC-39 (KB8). All PCR were done using Ac-
cupol DNA polymerase (PGS Scientifics Corp., Gaith-
ersburg, MD) with the following settings: 94°C for 5
min initially and then 94°C for 1 min, 56°C for 2 min,
72°C for 3 min; 25 cycles. These primers generated
PCR products for the HeV F and HeV G ORFs flanked
by SalI sites, with an additional PmeI site flanking
each SalI site, and the 59 end of each gene possessed
the sequence CACC upstream of the initial ATG. All
PCR products were gel purified (Qiagen, Valencia, CA).
After gel purification, HeV F and HeV G were sub-
cloned into a TOPO vector (Invitrogen Corp., Carlsbad,
CA). The TOPO constructs were then digested with
SalI and inserted into the SalI site of pMCO2. All
constructs were initially screened by restriction diges-
tion and further verified by sequencing. The recombi-
nant viruses were then obtained using standard tech-
niques employing tk selection and E. coli b-glucuron-
idase (GUS) staining (Broder and Earl, 1999). Briefly,
CV-1 cells were transfected with either pMCO2 HeV F
or pMCO2 HeV G using a calcium phosphate trans-
fection kit (Promega, Corp., Madison, WI). These
monolayers were then infected with Western Reserve
(WR) wild-type strain of vaccinia virus at a multiplicity
of infection (m.o.i.) of 0.05 PFU/cell. After 2 days the
cell pellets were collected as crude recombinant virus
stocks. TK2 cells were infected with the recombinant
crude stocks in the presence of 25 mg/ml 5-bromo-29-
deoxyuridine (BrdU) (Calbiochem, La Jolla, CA). After
2 h the virus was replaced with an EMEM-10 overlay
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132 BOSSART ET AL.containing 1% low-melting-point (LMP) agarose (Life
Technologies, Gaithersburg, MD) and 25 mg/ml BrdU.
After 2 days of incubation an additional EMEM-10
overlay containing 1% LMP agarose, 25 mg/ml BrdU,
and 0.2 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-glucu-
ronic acid (Clontech, Palo Alto, CA) was added. Within
24–48 h blue plaques were evident, picked, and sub-
jected to two more rounds of double-selection plaque
purification. The recombinant vaccinia viruses vKB1
(HeV F) and vKB2 (HeV G) were then amplified and
purified. Bacteriophage T7 RNA polymerase was pro-
duced by infection with vTF7-3, which contains the T7
RNA polymerase gene linked to a vaccinia virus pro-
moter (Fuerst et al., 1986). The E. coli LacZ gene linked
to the T7 promoter was introduced into cells by infec-
tion with vaccinia virus recombinant vCB21R–LacZ,
which was described previously (Alkhatib et al.,
1996a). For cell fusion assays, either we infected cells
with the appropriate vaccinia virus encoding the HeV F
or G or we transfected cell monolayers with the
pMC02-based plasmid constructs containing these
genes followed by infection 4 h later with WR vaccinia
virus. Transfection of monolayers was performed with
DOTAP (Roche Diagnostics Corp., Indianapolis, IN).
Cell–cell fusion assays
Fusion between HeV glycoprotein-expressing cells
and target cells was measured by a reporter gene assay
in which the cytoplasm of one cell population contained
vaccinia virus-encoded T7 RNA polymerase and the cy-
toplasm of the other contained the E. coli LacZ gene
linked to the T7 promoter; b-Gal is synthesized only in
fused cells (Nussbaum et al., 1994). Vaccinia virus-en-
coded proteins were produced by incubating infected
cells at 31°C overnight (Berger et al., 1995). Cell–cell
fusion reactions were conducted with the various cell
mixtures in 96-well plates at 37°C. Typically, the ratio of
HeV glycoprotein-expressing cells to target cells was 1:1
(2 3 105 total cells per well, 0.2-ml total volume). Cyto-
ine arabinoside (40 mg/ml) was added to the fusion
eaction mixture to reduce nonspecific b-Gal production
(Berger et al., 1995). For quantitative analyses, Nonidet-
40 was added (0.5% final) at 2.5 h and aliquots of the
ysates were assayed for b-Gal at ambient temperature
ith the substrate chlorophenol red-D-galactopyranoside
Roche Diagnostics Corp.). For inhibition by peptides,
erial dilutions of peptides were performed and added to
eV glycoprotein-expressing effector cells immediately
rior to the addition of target cell populations. For inhi-
ition by HeV-specific antisera, serial dilutions of the
arious rabbit sera were performed and added to HeV
lycoprotein-expressing effector cells just prior to the
ddition of target cells. All assays were performed in
uplicate and fusion results were calculated and ex-
ressed as rates of b-Gal activity (change in optical
a
gdensity at 570 nm per minute 3 1000) (Nussbaum et al.,
1994).
Peptide synthesis
The following hydrophilic peptide sequences were
chosen for synthesis and immunization based on analy-
sis of the hydrophobicity plots of the HeV F and G
glycoproteins: CKGITRKYKIKSNPLTKDIVIK (F2) and
CKSDSGDYNQKYIATKVERGKKDK (G1). Another 42-ami-
no-acid peptide corresponding to the C-terminal a-heli-
al heptad domain of HeV F was also synthesized, HQ-
IQTKVDISSQISSMNQSLQQSKDYIKEAQKILDTVNPSL
FC1). The sequence of peptide FC1 was based on the
ublished sequence (Gould, 1996), which was later cor-
ected (GenBank Accession No. AF017149) (Wang et al.,
000), and the first 6 residues of the N-terminus of FC1
re irrelevant; however, this change is distant from the
eucine zipper region and did not affect the peptide’s
ctivity. A control 44-amino-acid peptide derived from the
ytoplasmic tail of the IL-2 receptor gamma chain pro-
ein, LERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKG-
AESLQPDYS (IL2Rg), was used as the irrelevant control.
ynthesis of each peptide was accomplished on an
pplied Biosystems Model 433 Peptide Synthesizer us-
ng HBTU/HOBt activation on a hydroxmethlphenoxym-
thyl-copolystyrene-1% divinylbenzene resin. Upon syn-
hesis completion, the resin was washed twice with
ichloromethane (DCM) followed by three washes with
ethanol and allowed to dry. Cleavage of the peptide
rom the resin was obtained using Reagent R (90% tri-
luroacetic acid (TFA), 5% thioanisole, 3% 1,2-ethanedi-
hiol, and 2% anisole) at room temperature for 3 h. The
eptide was isolated from the mixture by vacuum filtra-
ion through a sintered glass funnel into cold ethyl ether,
hich permitted precipitation. Peptide and ether were
ransferred to a 50-ml centrifuge tube and centrifuged.
he peptide pellet was resuspended in cold ether and
entrifuged three separate times to remove residual
cavengers and acid. Following the third wash the pellet
as allowed to dry completely. Once dry, the peptide
as resuspended in 95% water/5% CH3CN (the pH was
adjusted to ;7 using dilute NH4OH), frozen at 220°C,
and lyophilized.
Polyclonal antibodies
Peptide-specific rabbit sera to the HeV F and G glyco-
proteins were prepared with the Imject Maleimide Acti-
vated KLH Kit (Pierce, Rockford, IL). The F2 and G1
synthetic peptides were reduced with 250 mM dithiothre-
tol (DTT) (ICN Biomedicals, Cleveland, OH) for 1 h at
7°C prior to conjugation. Excess DTT was removed
sing 1800 MW gel exclusion columns (Pierce). Then
.56 mg of recovered G1 was conjugated to 2 mg of
ctivated KLH and 1.25 mg of recovered F2 was conju-
ated to 2 mg of activated KLH. Conjugates were purified
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133HENDRA VIRUS ENVELOPE GLYCOPROTEINSusing a 5000 MW gel exclusion column (Pierce). Each
peptide–KLH conjugate was stored in 200-mg aliquots at
80°C. Two hundred micrograms of F2-KLH conjugate
ontaining 13 RIBI (RiBi Immunochem Research Inc.,
amilton, MT) in 1 ml PBS and 200 mg G1–KLH conju-
ate containing 13 RIBI in 1 ml PBS were administered
ndependently to two rabbits as follows: 0.05 ml intrader-
al at six sites, 0.3 ml into each hind leg, and 0.1 ml
ubcutaneous in the neck region. Equivalent boosts
ere given on days 28, 56, and 84. Test bleeds were
ollected on day 35, and crop bleeds were collected on
ays 63 and 91. In addition, serum from a rabbit immu-
ized with gamma-irradiated HeV was also used in some
xperiments.
etabolic labeling and immunoprecipitation
For labeling of HeV glycoproteins expressed by re-
ombinant vaccinia viruses, HeLa cells were infected at
m.o.i. of 10 PFU/cell. At 6 h postinfection, monolayers
ere washed, overlaid with methionine- and cysteine-
ree minimal essential medium (Life Technologies) con-
aining 2.5% dialyzed fetal calf serum (Life Technologies)
nd 100 mCi of 35S-labeled ProMix/ml (Amersham Phar-
acia Biotech, Piscataway, NJ), and incubated overnight.
lternatively, a pulse–chase labeling procedure was per-
ormed where after 8 h of infection the cells were pulsed
ith 100 mCi of 35S-labeled ProMix/ml for 15 min and then
hased with a 200-fold excess of methionine and cys-
eine for 1 h. Lysis of cells was performed in 100 mM
ris–HCl (pH 8.0), 100 mM NaCl, 0.5% Triton X-100. Typ-
cally, 0.5–1.0 ml of antiserum or normal rabbit serum was
utilized per immunoprecipitation. Incubations for at least
1 h at room temperature were followed by addition of
Protein G–Sepharose for at least 30 min. Complexes
were washed twice with lysis buffer (100 mM Tris–HCl
(pH 8.0), 100 mM NaCl, 0.5% Triton X-100) and once with
DOC buffer (100 mM Tris–HCl (pH 8.0), 100 mM NaCl,
0.1% sodium deoxycholate, 0.1% SDS). Proteins were sep-
arated by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE) (10%) and visualized by autoradiography.
Western blot analysis
BSC-1 cell monolayers were infected overnight at a
m.o.i. of 10 with vaccinia virus encoding wild-type HeV F
or HeV G. Cells were extracted with 0.5% Triton X-100 in
100 mM Tris–HCl, pH 8.0, 100 mM NaCl and the nuclei
were removed by centrifugation. Samples were prepared
by boiling in sample buffer containing 2-mercaptoetha-
nol. Extracts from 5 3 104 cells (total) were loaded per
ell onto a 10% SDS–PAGE gel. Following transfer to
itrocellulose paper, the blot was probed with either
eptide-specific or virus-specific rabbit antiserum. The
lot was then incubated with HRP-conjugated rabbit anti-abbit IgG and developed with the SuperSignal chemilu-
inescence kit (Pierce).ACKNOWLEDGMENTS
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